Browsing by Author "Baskol, Dilsah"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Carbapenem-resistant Gram-negative pathogens associated with septic shock: A review of 120 cases
    (Taylor & Francis Ltd, 2022-04-16) Önal, Uğur; Akyol, Deniz; Mert, Merve; Baskol, Dilsah; Memetali, Seichan Chousein; Sanlidag, Gamze; Kenanoglu, Buse; Uyan-Onal, Ayse; Quliyeva, Gunel; Avsar, Cansu Bulut; Akdag, Damla; Demir, Melike; Erdem, Huseyin Aytac; Kahraman, Umit; Bozbiyik, Osman; Ozgiray, Erkin; Bozkurt, Devrim; Akarca, Funda Karbek; Demirag, Kubilay; Cankayali, Ilkin; Uyar, Mehmet; Cilli, Feriha; Arda, Bilgin; Yamazhan, Tansu; Pullukcu, Husnu; Tasbakan, Meltem Isikgoz; Sipahi, Hilal; Ulusoy, Sercan; Sipahi, Oguz Resat; ÖNAL, UĞUR; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı,; 0000-0001-6953-8499 ; ACQ-7832-2022
    This study aimed to evaluate the influencing variables for outcomes in patients with septic shock having culture-proven carbapenem-resistant Gram-negative pathogens. It included 120 patients (mean age 64.29 +/- 1.35 years and 58.3% female). The mean Sequential Organ Failure Assessment score during septic shock diagnosis was found to be 11.22 +/- 0.43 and 9 +/- 0.79 among the patients with mortality and among the survivors, respectively (P = 0.017). The logistic regression analysis showed that empirical treatment as mono Gram-negative bacteria-oriented antibiotic therapy (P = 0.016, odds ratio (OR) = 17.730, 95% confidence interval (CI): 1.728-182.691), Charlson Comorbidity Index >2 (P = 0.032, OR = 7.312, 95% CI: 5.7-18.3), and systemic inflammatory response syndrome score 3 or 4 during septic shock diagnosis (P = 0.014, OR = 5.675, 95% CI: 1.424-22.619) were found as independent risk factors for day 30 mortality. Despite early diagnosis and effective management of patients with septic shock, the mortality rates are quite high in CRGNP-infected patients.
  • No Thumbnail Available
    Publication
    Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: An analysis of 53 cases
    (Springer, 2023-10-01) Onal, Ugur; Akyol, Deniz; Kaya, Arda; Baskol, Dilsah; Kenanoglu, Buse; Sanlidag, Gamze; Onal, Ayse Uyan; Avsar, Cansu Bulut; Mert, Merve; Memetali, Seichan; Erdem, Hueseyin Aytac; Bozkurt, Devrim; Simsir, Adnan; Bozbiyik, Osman; Kahraman, Umit; Ozgiray, Erkin; Korkmaz, Pervin; Cilli, Feriha; Pullukcu, Husnu; Yamazhan, Tansu; Tasbakan, Meltem Isikgoz; Arda, Bilgin; Ulusoy, Sercan; Sipahi, Oguz Resat; ÖNAL, UĞUR; 0000-0001-6194-3254; JCO-3678-2023
    Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.